REGENXBIO Inc. (RGNX) Q2 2024 Earnings Call Transcript
https://seekingalpha.com/article/4709563-regenxbio-inc-rgnx-q2-2024-earnings-call-transcript?source=feed_sector_transcripts
Aug 01, 2024 - REGENXBIO Inc. (NASDAQ:NASDAQ:RGNX) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ETCompany ParticipantsPatrick Christmas - CLOCurran Simpson -...
0
Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2314680/regenxbio-rgnx-reports-q2-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2314680
Aug 01, 2024 - Regenxbio (RGNX) delivered earnings and revenue surprises of 18.60% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
0
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
https://www.zacks.com/stock/news/2291689/fda-expands-sarepta-s-srpt-dmd-gene-therapy-label?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2291689
Jun 21, 2024 - Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
0